177 related articles for article (PubMed ID: 36434635)
1. High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective study.
Takamizawa S; Yazaki S; Kojima Y; Yoshida H; Kitadai R; Nishikawa T; Shimoi T; Sudo K; Okuma HS; Tanioka M; Noguchi E; Uno M; Ishikawa M; Kato T; Fujiwara Y; Yonemori K
BMC Cancer; 2022 Nov; 22(1):1215. PubMed ID: 36434635
[TBL] [Abstract][Full Text] [Related]
2. Use of mesothelin as a tumor-associated antigen in cervical squamous cell carcinoma.
He Y; Zhao H; Li XM; Yin CH; Wu YM
Gene; 2019 Mar; 690():30-37. PubMed ID: 30583024
[TBL] [Abstract][Full Text] [Related]
3. Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression.
Kitadai R; Nishikawa T; Yoshida H; Mizoguchi C; Yamamoto K; Kato T; Yonemori K
J Gynecol Oncol; 2024 Mar; 35(2):e11. PubMed ID: 37914528
[TBL] [Abstract][Full Text] [Related]
4. High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma.
Chu GJ; Linton A; Kao S; Klebe S; Adelstein S; Yeo D; Rasko JEJ; Cooper WA
Histopathology; 2023 Aug; 83(2):202-210. PubMed ID: 37040900
[TBL] [Abstract][Full Text] [Related]
5. Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET.
Xia S; Duan W; Xu M; Li M; Tang M; Wei S; Lin M; Li E; Liu W; Wang Q
J Exp Clin Cancer Res; 2024 Apr; 43(1):103. PubMed ID: 38570866
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin Expression is Correlated with Chemoresistance in Stage IV Colorectal Cancer.
Nagata K; Shinto E; Shiraishi T; Yamadera M; Kajiwara Y; Mochizuki S; Okamoto K; Einama T; Kishi Y; Ueno H
Ann Surg Oncol; 2021 Dec; 28(13):8579-8586. PubMed ID: 34318385
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC).
Le K; Wang J; Zhang T; Guo Y; Chang H; Wang S; Zhu B
Int J Med Sci; 2020; 17(4):422-427. PubMed ID: 32174772
[No Abstract] [Full Text] [Related]
8. Mesothelin Expression in Patients with High-Grade Serous Ovarian Cancer Does Not Predict Clinical Outcome But Correlates with CD11c
Magalhaes I; Fernebro J; Abd Own S; Glaessgen D; Corvigno S; Remberger M; Mattsson J; Dahlstrand H
Adv Ther; 2020 Dec; 37(12):5023-5031. PubMed ID: 33052561
[TBL] [Abstract][Full Text] [Related]
9. High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer.
Yazaki S; Kojima Y; Yoshida H; Takamizawa S; Kitadai R; Nishikawa T; Shimoi T; Sudo K; Saito A; Okuma HS; Tanioka M; Noguchi E; Uno M; Ishikawa M; Kato T; Fujiwara Y; Ohe Y; Yonemori K
J Gynecol Oncol; 2022 Nov; 33(6):e82. PubMed ID: 36245230
[TBL] [Abstract][Full Text] [Related]
10. Interpatient variability in mesothelin expression necessitates its evaluation before gastric cancer immunotherapy.
Sotoudeh M; Mansouri V; Shakeri R; Sharififard B; Sajadi N; Naderi M
Immunotherapy; 2022 May; 14(7):531-538. PubMed ID: 35321580
[No Abstract] [Full Text] [Related]
11. Construction of a
Hou X; Wang F; Meng X; Li D; Ding J; Chen Y; Wang Z; Zhu H; Yang Z
Mol Pharm; 2022 Oct; 19(10):3623-3631. PubMed ID: 35904514
[TBL] [Abstract][Full Text] [Related]
12. Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.
Awuah P; Bera TK; Folivi M; Chertov O; Pastan I
Mol Cancer Ther; 2016 Jul; 15(7):1648-55. PubMed ID: 27196771
[TBL] [Abstract][Full Text] [Related]
13. Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer.
Inoue S; Tsunoda T; Riku M; Ito H; Inoko A; Murakami H; Ebi M; Ogasawara N; Pastan I; Kasugai K; Kasai K; Ikeda H; Inaguma S
Oncol Lett; 2020 Mar; 19(3):1741-1750. PubMed ID: 32194667
[TBL] [Abstract][Full Text] [Related]
14. Generation of a Novel Mesothelin-Targeted Oncolytic
Froechlich G; Gentile C; Infante L; Caiazza C; Pagano P; Scatigna S; Cotugno G; D'Alise AM; Lahm A; Scarselli E; Nicosia A; Mallardo M; Sasso E; Zambrano N
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33418877
[TBL] [Abstract][Full Text] [Related]
15. Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.
Liu XF; Onda M; Schlomer J; Bassel L; Kozlov S; Tai CH; Zhou Q; Liu W; Tsao HE; Hassan R; Ho M; Pastan I
Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2317283121. PubMed ID: 38227666
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
[TBL] [Abstract][Full Text] [Related]
17. Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types.
Lamberts LE; de Groot DJ; Bense RD; de Vries EG; Fehrmann RS
Oncotarget; 2015 Sep; 6(29):28164-72. PubMed ID: 26172299
[TBL] [Abstract][Full Text] [Related]
18. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
Cerise A; Bera TK; Liu X; Wei J; Pastan I
Clin Colorectal Cancer; 2019 Sep; 18(3):192-199.e1. PubMed ID: 31345777
[TBL] [Abstract][Full Text] [Related]
19. An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin.
Snell D; Gunde T; Warmuth S; Chatterjee B; Brock M; Hess C; Johansson M; Simonin A; Spiga FM; Weinert C; Kirk N; Bassler N; Campos Carrascosa L; Flückiger N; Heiz R; Wagen S; Giezendanner N; Alberti A; Yaman Y; Mahler D; Diem D; Lichtlen P; Urech D
Oncoimmunology; 2023; 12(1):2233401. PubMed ID: 37456982
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
